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Summary Reductions in cell-cell adhesion and stromal and vascular invasion are essential steps in the progression from localized
malignancy to metastatic disease. In this study, changes in the expression of the components of the E-cadherin-catenin cell adhesion
complex have been investigated using immunohistochemical techniques in primary tumours and nodal metastases from 36 patients with
squamous cell carcinoma of the head and neck. For 14 patients the corresponding primary and nodal metastases samples were available.
None of the 51 samples showed normal E-cadherin expression when compared with either the adjacent normal squamous epithelium or with
normal colonic epithelium that was used as positive control material. In 88% of primary tumours fewer than 50% of cells exhibited normal
membranous E-cadherin expression. Loss of membranous E-cadherin expression was more extensive in poorly differentiated carcinomas
while, in individual carcinomas, membranous E-cadherin expression was stronger in those parts of the neoplasm that expressed the
differentiation marker involucrin. Expression of P-catenin generally paralleled that of E-cadherin, but in 12 cases there was strong
membranous P-catenin expression in samples that exhibited predominantly cytoplasmic E-cadherin labelling. Expression of a-catenin was
generally weak and did not correlate with the expression of either P-catenin or E-cadherin. Marked intratumoral heterogeneity for protein
expression was evident for all antibodies, and the abnormal expression of the catenins is a novel finding. E-cadherin is expressed
more intensely in cells with greater squamous differentiation, but there was no correlation between the decreased expression of any of the
adhesion molecules of the E-cadherin complex tested and local recurrence, metastasis or survival. The loss of expression of components of
the E-cadherin complex is a common abnormality in squamous carcinomas and, while it may be permissive for metastasis, it does not appear
to be the only determinant of this process.
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The clinical course of squamous cell carcinoma of the head and
neck (SCCHN) is determined by both host and tumour factors
(Bloom et al, 1984). Tumour size, degree of differentiation and
stage at the time of presentation are important prognostic indica-
tors (Cachin, 1975; Hibbert et al, 1983). However, it is the pres-
ence or absence of lymph node metastasis that is the most
important prognostic indicator (Jones et al, 1993). Thus the identi-
fication of those patients with primary tumours that are likely to
develop lymph node metastases is of major importance in the
choice of treatment. For metastasis to occur, cells need to detach
from their neighbours, migrate through the basement membrane
and interstitial matrix, and invade the lymph and blood transport
systems (Liotta et al, 1988; Ponta et al, 1994). Tumour cells
exhibit reduced intercellular adhesion compared with normal cells,
consistent with the down-regulation, or loss offunction, of one of
the key adhesion molecules responsible for the maintenance ofthe
orderly structure ofdifferentiated tissue. Changes or alterations in
the function and expression ofthe cell-cell adhesion molecule, E-
cadherin, have been postulated to be an early event in the multi-
step process oftumour metastasis and an important determinant of
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malignant tumourprogression (Birchmeier et al, 1993; Ponta et al,
1995). E-cadherin is one of a family of functionally related integ-
ral membrane glycoproteins responsible for calcium-dependent
cell-cell adhesion (Takeichi, 1991). Human carcinoma cell lines
that are negative for E-cadherin expression have been shown to be
invasive in two in vitro invasion assay systems (Kinsella et al,
1994a), and transfection with an E-cadherin cDNA has been
shown to suppress the invasive phenotype of human breast and
colorectal carcinoma cell lines (Frixen et al, 1991; Kinsella et al,
1994a). Moreover, colorectal tumour cells deprived of their E-
cadherin function by the addition of anti-E-cadherin antibody
become invasive in thecollagen gel assay and adopt a more single-
cell morphology on plastic (Kinsella et al, 1994a). Reduced E-
cadherin expression has been shown to correlate with advanced
disease in carcinomas of the breast (Oka et al, 1993), prostate
(Umbas et al, 1992) and bladder (Bringuier et al, 1993), but the
correlation is weaker for carcinoma of the colon (Kinsella et al,
1993; Gagliardi et al, 1995), gastric carcinoma (Mayer et al, 1993)
and SCCHN (Schipper et al, 1991; Bowie et al, 1993; Mattjssen et
al, 1993; Kinsella et al, 1994b).
Recently the cytoplasmic carboxy terminus of the E-cadherin
molecule has been shown to be linked to the actin cytoskeleton via
a- and fB-catenin (McCrea et al, 1991; Ozawa and Kemler, 1992;
Knudsen et al, 1995). The catenins are essential for E-cadherin
function (Shimoyama et al, 1992; Oyama et al, 1994; Kawanishi et
al, 1995). E-cadherin is directly associated with 1-catenin via the
internal Armadillo-like repeat region of the 1-catenin molecule
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Table I Host and tumour details of patients
Patient data n
Male (mean age) 26 (65 years)













Stage of primary tumour (T stage)
T 1-2 17
T 3-4 19





aEastern Cooperative Oncology Group. 0, Fit and well; 1, capable of light
work; 2, incapable of work, spends up to half a day in bed; 3, spends more
than half a day in bed; 4, moribund.
and is indirectly linked via the a-catenin/,-catenin heterodimeric
complex to a-catenin (Alberle et al, 1994; Oyama et al, 1994;
Stappert and Kemler, 1994). E-cadherin also competes with the
product of the colonic tumour-suppressor gene, APC (adenoma-
tous polyposis coli), to bind to the internal Armadillo-like repeats
of ,B-catenin (Rubinfeld et al, 1993; Su et al, 1993; Hulsken et al,
1994), while a-catenin links the E-cadherin-catenin complex to
a-actinin and the actin cytoskeleton (Knudsen et al, 1995).
Furthermore, it has been suggested that immunohistochemical
analysis of changes in a-catenin expression in gastric carcinomas
might be a better indicator of the propensity of tumours to metas-
tasize than E-cadherin (Matsui et al, 1994). a-Catenin down-
regulation has also been reported to be responsible for a more
invasive phenotype in colon tumour cells (Vermeulen et al, 1995),
while re-expression of a-catenin has been reported to suppress
tumorgenicity in prostate cells (Ewing et al, 1995).
In the present study, we have examined 51 samples from 36
patients with SCCHN for expression of E-cadherin and a- and P-
catenin using immunohistochemical techniques and correlated this
with the expression ofa putative markerofepithelial cell differen-
tiation, involucrin (Hudson et al, 1992). The prognostic implica-
tions of changes in expression of the components of the
E-cadherin-catenin complex are discussed in relation to other
prognostic indicators and patient outcome.
MATERIALS AND METHODS
Samples
Fifty-one primary tumour and lymph node metastasis samples
were obtained from 26 male and 10 female patients (mean age 62
years) presenting with squamous carcinomas ofthe head and neck
(Table 1). Each resected specimen was collected fresh from the
operating theatre and delivered to the pathology department with
minimal delay. Each specimen was examined by a pathologist and
samples were taken from the primary site and involved lymph
nodes, frozen in liquid nitrogen and stored at -80°C. The speci-
mens were then fixed in 10% neutral buffered formalin followed
by overnightprocessing to paraffin wax and then diagnostic evalu-
ation. Representative blocks were selected for this study once
the diagnostic evaluation was complete. Twenty patients did not
have metastatic disease at the time of operation and have not
developed metastases up to 2 years later. For 14 patients, samples
of the primary and corresponding nodal metastases were
available. Overall, 18 lymph node specimens and 33 primary
tumours were studied.
Data entry
Clinical data were stored on a purpose-designed database, and
outcome details and details of follow-up of patients were recorded
from clinic visits from the general practitioner records and from the
Merseyside and Cheshire CancerRegistry. The stage ofthe primary
tumour and nodal metastases were classified or reclassified using
theUICC system (Hermanek and Sobin, 1992) and theperformance
status was classified using the ECOG scale (Zubrod et al, 1960).
The degree ofdifferentiation of the carcinomas was independently
assessed by a pathologist, based on the extent ofkeratinization and
nuclear pleomorphism in haematoxylin and eosin-stained sections
taken in parallel to those used for immunohistochemistry.
Antibodies used and their specificities
E-cadherin was detected using the human epithelial cadherin-1
(HECD-1) mouse monoclonal IgG (British Biotechnology,
Abingdon, UK) against the 150-kDa carboxy-terminal fragment to
human E-cadherin. Both a- and ,-catenin were detected using
anti-a- and anti-p-catenin mouse monoclonal IgG (Affinity
Research, Mamhead Castle, UK). The a-catenin was raised
againstthe 19.4-kDaC-terminal fragment, while theP-catenin was
raised against the 23-kDa C-terminal fragment. Involucrin was
detected using the human involucrin mouse IgG against the
102-kDa fragment (Sigma Aldrich). The immunolabelling by all
the antibodies was performed using the streptavidin-biotin
complex method, using the streptavidin ABC kit (Dako, High
Wycombe, UK). The optimal dilutions for the antibodies were
established in preliminary experiments.
Immunolabelling protocol
Paraffin sections (4 gm) were cut and dewaxed in xylene for
10 min and then placed in two changes ofalcohol (90% and 100%)
before immersion in methanol and hydrogen peroxide (3%) for
20 min to block endogenous peroxidases. Normal tap water was
then used to wash the sections (5 min) followed by 2-min washes
in Tris (hydroxymethyl) methylamine-buffered saline (TBS) (pH
7.6). To enhance E-cadherin and a- and 0-catenin staining in
formalin-fixed paraffin-embedded tissues, sections were treated
with an antigen-retrieval solution in a microwave oven. This
method of antigen unmasking denatures proteins and allows
linearized strands to be more fully exposed to the detection
method (Norton et al, 1993). Briefly, the slides were immersed
in 0.01 M citrate buffer (made from citric acid and balanced to a
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Table 2 Histological grade of primary tumour and tumour factors
Tumour factors Well/moderately Poorly X2P
differentiated differentiated
(n = 13) (n = 23)
Site
Mouth and oropharynx 7 9
Larynx 2 4 X2 = 0.5511
Hypopharynx 3 7 P= 0.7592
Other 1 3
Stage of primary tumour (T stage)
T 1-2 7 10 Xi = 0.01690
T3-4 6 12 P= 0.8966
Stage of neck node disease (N stage)
NO 7 10 X2 = 0.0630
Ni 2 4 P=0.8018
N2 2 6
N3 2 3
Two-year survival 60% (25-82) 65% (27-86) X2(peto) = 0.5234
%2 = X with two degrees of freedom.
Table 3 The percentage of cells showing exclusively membranous
expression of E-cadherin in primary carcinomas with and without nodal
metastases
Cells with Primary carcinomas Primary carcinomas Nodal
membranous without metastases with metastases metastases
labelling (%)
76-100 2 1 0
51-75 0 1 1
26-50 7 0 3
0-25 10 12 14
pH of 6.0) and heated in a 650-watt microwave on full power for
15 min. The slides were then rinsed in TBS, placed in a Shandon
sequensa and non-specific binding was blocked with 100 pl of
normal goat serum (Vector, Peterborough, UK) at a dilution of
1:20 for 10 min. One hundred microlitres of antibody were added
to each section. HECD-1 was incubated at a dilution of 1:200 at
38°C for 2 h. a-Catenin was incubated at a dilutionof 1:20 at 370C
for 2 h and 3-catenin was incubated at a dilution of 1:100 for 1 h at
room temperature.
After incubation with the primary antibodies, the slides were
washed for5 min using TBS. One hundred microlitres ofabiotiny-
lated secondary mouse antibody (Amersham) was then applied at a
dilution of 1:200 for 45 min, washed in TBS for 5 min and incu-
bated with 100pl of 1:200 streptavidin-biotin complex for30 min.
After washing with TBS, visualization was achieved with 100 pl
of diaminobenzidine (DAB) at a concentration of 1 mg per 10 ml
(Sigma Aldrich).
Colonic epithelium was used as a positive control for the E-
cadherin and oc- and ,-catenin staining. This tissue type was
chosen because of its high antigenicity for the respective mole-
cules. In addition, when possible, the primary tumour blocks were
selected to include normal squamous epithelium, which provided
an internal positive control. The antigen-retrieval method was vali-
dated in preliminary experiments by immunolabelling of frozen
sections of carcinoma without microwave pretreatment. The
appearances of the sections were identical to those of the paraffin
sections subjected to the antigen-retrieval method, confirming that
this technique does not produce spurious positivity in this situa-
tion. All sections were assessed by two independent observers.
The pattern of immunolabelling was described as normal for
all three adhesion molecules when labelling was exclusively
membranous with no cytoplasmic labelling and ofsimilarintensity
to adjacent normal epithelium. Abnormal labelling included
discontinuous or absent membranous labelling, with or without
cytoplasmic labelling. For each antigen, the cases were grouped
according to whether 76-100%, 51-75%, 26-50% or 0-25% of
cells showed the normal pattern ofstrong membranous staining.
Double immunolabelling for E-cadherin and involucrin
expression
For this procedure, E-cadherin was developed first, followed by
involucrin. The immunolabelling procedure for E-cadherin was as
described above except that the sections were incubated with anti-
body overnight at 4°C and a tertiary antibody, swine anti-rabbit
(Amersham), was used for 30 min at a dilution of 1:100 to enhance
epitope recognition. Antibody binding was amplified using rabbit
peroxidase anti-peroxidase (Dako, High Wycombe, UK) and visu-
alization was achieved with DAB. The same sections were then
incubated with the antibody to involucrin at a dilution of 1:100 for
1 h at room temperature. After washing with TBS, biotinylated
mouse secondary antibody was applied as described previously.
Detection of the epitope was achieved using an avidin-biotin
/alkaline phosphatase complex (Dako, High Wycombe) at a dilu-
tion of 1:100 for 30 min. After washing, visualization was
achieved using fast red. The fast red solution was made by
dissolving 5 mg offast red powder (Merck, Leicestershire, UK) in
5 ml of TBS with the addition of two drops of solutions 1 and 2
from the alkaline phosphatase substrate kitfollowed by three drops
of levamisole (Vector, Peterborough, UK). This solution was
placed on the sections for 10 min until the sections became red,
after which they were washed in TBS and mounted in aqueous
mountant.
Statistical analysis
As the data were not normally distributed, non-parametric methods
of analysis were used. The Wilcoxon signed-rank test and rank-
sum tests were used when comparing cell adhesion parameters.
Categorical data were displayed in contingency tables when
analysing all adhesion parameters with respect to clinicopatholog-
ical data and analysed by chi-square. Categorical data were further
analysed using the multivariate method of categorical modelling
(SAS Institute, 1985). Survival times were calculated using the life-
table method (Armitage and Berry, 1987) using the Lifereg proce-
dure on the SAS software (SAS Institute, 1985). Differences in
survival were investigated using the log-rank test (Peto et al, 1977).
RESULTS
Host and tumour details of all 36 patients are shown in Table 1.
There was no significant association between histological grade
and host and tumour factors either on univariate or multivariate
analysis (Table 2). Histological grade did not affect survival(x2I =
0.5234). In addition, there was no significant difference between
the histological grade ofthe primary tumours that developed nodal
metastases vs those that did not (P = 0.2378). The histological
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Figure 1 (A) Strong membranous E-cadherin expression in a moderately
to well-differentiated primary squamous carcinoma. Scale bar = 25 ,um.
(B) Weak membranous E-cadherin labelling in the nodal metastasis. Scale
bar = 25 ,um
grade of lymph node metastases, however, tended to be poorer
than the originating primary (P = 0.0001).
Patterns of expression in normal epithelium
E-cadherin showed membranous labelling in all the cells in the
lower half of the normal squamous epithelium. Membranous P-
catenin expression was observed in the lower 30-70% of cells in
normal keratinizing squamous carcinomas, while membranous x-
catenin expression was absent in the basal layer. All the antibodies
showed strong membranous labelling ofcolonic epithelium.
Patterns of expression in primary carcinomas and
nodal metastases
E-cadherin
None of the primary carcinomas or nodal metastases showed
normal E-cadherin expression in 100% ofcells (Table 3). The loss
of strictly membranous E-cadherin expression was accompanied
by the appearance ofcytoplasmic expression in 29 out of 33 ofthe
primary carcinomas. In the primary tumour sample shown (Figure
1A), E-cadherin expression was stronger than in the corresponding
nodal metastases (P = 0.0008). Membranous expression was
generally weaker, and cytoplasmic expression was generally
Figure 2 (A) Strong membranous l-catenin labelling in a moderately to well-
differentiated primary squamous carcinomas. Scale bar = 25 gm. (B) Weak
membranous f-catenin labelling in the nodal metastasis. Scale bar = 25 gm
Table 4 The percentage of cells showing exclusively membranous
expression of 1-catenin in primary carcinomas with and without nodal
metastases
Cells with Primary carcinomas Primary carcinomas Nodal
membranous without metastases with metastases metastases
labelling (%)
76-100 3 2 2
51-75 4 4 4
26-50 7 3 5
0-25 6 5 8
greater in nodal metastases than in the corresponding primary
carcinomas (Figure 1B). There was no significant difference in the
pattern of membranous E-cadherin expression between those
tumours with and without nodal metastases (P = 0.2960).
Moreover there was no significant association, using either
univariate or multivariate analysis, between host and tumour
factors and E-cadherin. No correlation was observed between the
proportion of cells showing membranous E-cadherin expression
and patient survival (P = 0.3748).
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Figure 3 (A) Weak membranous E-cadherin labelling in a poorly
differentiated primary carcinoma. Scale bar = 25 gm. (B) Strong
membranous I-catenin labelling in a poorly differentiated primary carcinoma.
Scale bar = 25 ,im
Figure 4 (A) Weak membranous a-catenin labelling in a moderately to
well-differentiated primary squamous carcinoma. Scale bar = 25 ,um. (B)
Lack of membranous expression of a-catenin in the nodal metastases.
Scale bar = 25 ,um
Table 5 The percentage of cells showing exclusively membranous
expression of a-catenin in primary carcinomas with and without nodal
metastases
Cells with Primary carcinomas Primary carcinomas Nodal
membranous non-metastasizing metastasizing metastases
labelling (%)
76-100 0 0 0
51-75 0 1 0
26-50 2 1 0
0-25 17 12 18
a- and /-catenin
None of the carcinomas showed membranous expression of either
ofthe catenins in 100% ofcells. Again the catenins were looked at
in the same patient using the same series of primary and nodal
samples. The pattern of P-catenin expression generally followed
E-cadherin expression (Figure 2A depicting the primary carci-
noma and Figure 2B the nodal metastasis). Only 2 of the 51
samples exhibited low 3-catenin expression in the presence ofhigh
membranous E-cadherin expression. There were 12 cases where
high membranous f-catenin corresponded to predominantly
cytoplasmic E-cadherin labelling (Figure 3A depicting weak
Figure 5 Double labelling for E-cadherin and involucrin in a moderately to
well-differentiated primary squamous carcinoma. Scale bar = 40 gim
E-cadherin expression while figure 3B shows clear membranous
,-catenin labelling). No significant difference in the proportion of
cells showing membranous 3-catenin expression was observed
between the tumours of those patients that did not develop neck
node metastases and those that did (P = 0.5567) (Table 4).
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All tumour samples exhibited aberrant discontinuous a-catenin
expression. Figure 4A demonstrates severely reduced membra-
nous expression in the primary sample when compared with E-
cadherin and ,B-catenin, while the nodal sample showed no
membranous a-catenin expression (Figure 4B). There was no
difference in the proportion of cells expressing a-catenin between
the tumours of patients that did not develop neck node metastases
and those that did (P = 0.0581) (Table 5). The expression of both
variables was reduced in neck nodal metastases compared with the
primary tumour (a-catenin, P = 0.0059; ,B-catenin, P = 0.001)
Immunolabelling and differentiation
On double labelling for E-cadherin and involucrin, E-cadherin
expression was membranous and the involucrin expression was
cytoplasmic in normal epithelium. A strong correlation between
membranous E-cadherin labelling and involucrin expression was
observed when selected sections were double labelled for both
molecules with co-localization of E-cadherin and involucrin in
regions ofgood differentiation (Figure 5).
For all three adhesion molecules, expression was more intense
and more confined to the cell membranes in the better differenti-
ated areas of individual sections. Seventy-three per cent of the
nodal samples were poorly differentiated and generally exhibited
weaker membranous labelling and increased cytoplasmic labelling
for all three molecules than the primary samples.
DISCUSSION
Changes in cell adhesion molecules are accepted to have an impor-
tant role in facilitating the dissemination of tumour cells from the
primary site and the establishment ofmetastases. The expression of
the components ofthe E-cadherin cell adhesioncomplex have been
studied in a variety ofhuman carcinomas in an attempt to correlate
changes with advanced disease state and tumour progression.
Studies of E-cadherin expression both in squamous carcinomas
(Schipper etal, 1991; Bowie et al, 1993; Mattijssen et al, 1993) and
in vitro in tongue carcinoma cell lines (Kinsella et al, 1994b) have
failed to provide a clear picture for its role in SCCHN. Recently, it
has been observed that E-cadherin function is dependent on the
integrity ofthe cytoplasmic proteins a- andP-catenin (Shimoyama
et al, 1992; Kawanishi et al, 1995) and, in gastric carcinomas,
immunohistochemical analysis showed not only reduced or
heterogenous expression of E-cadherin but also reduced a-catenin
expression (Matsui et al, 1994; Ochia et al, 1994).
The immunohistochemical profile of the expression of E-
cadherin, a- and 3-catenin has not been determined previously in
SCCHN in relation to metastasis and patient survival. In the present
study we have evaluated the expression of these molecules in 51
samples of primary carcinomas and nodal metastases from 36
patients. For 14 patients, there were paired primary tumours and
nodal metastases, and 19 nodal metastases samples were examined
in total. None of the tumour samples showed normal E-cadherin
expression and 88% ofthe primary carcinomas had fewer than 50%
ofcells exhibiting strictly membranous E-cadherin expression. Loss
of membranous E-cadherin expression was associated with expres-
sion of E-cadherin in the cytoplasm. As the molecule has to be
present at the cell surface to mediate cell-cell adhesion, one can
speculate thatthe presence ofE-cadherin in thecytoplasm, by defin-
ition, means that it is non-functional (Gagliardi et al, 1995). A
reduction in the cell-cell adhesive properties ofgreater than 50% in
the majority of tumours is significant as the function of some cell
adhesion molecules is not linearly related to cell surface expression
(Hoffman and Edelman, 1983). With respect to a-catenin expres-
sion, 86% of the samples that showed less than 50% of cells with
membranous staining for E-cadherin also showed less than 50%
cells staining for a-catenin. Only three tumours with strong
membranous E-cadherin expression had negligible ax-catenin
expression. Similarly, only one sample withhigh E-cadherin expres-
sion had low 3-catenin expression. Thus, although loss of expres-
sion of a-catenin and P-catenin has previously been reported to be
important for E-cadherin functionality, the independent loss of
catenin expression is unlikely to be important in SCCHN. However,
as only a few well-differentiated carcinomas were studied in this
series, and E-cadherin expression is greater in well-differentiated
carcinomas, we cannot exclude the possibility that loss of catenin
expression may be important in some well-differentiated, metasta-
sizing carcinomas. As a high percentage of samples already have
reduced E-cadherin expression irrespective of their nodal status or
of the nodal status of the patient, changes in the localization of E-
cadherin correlate most strongly with the degree ofdifferentiation of
individual cells within a tumour. Differentiation status is a powerful
prognostic indicator for SCCHN (Cachin, 1975); however, in this
study, no correlation was observed between reduced membranous
E-cadherin expression and survival. None ofthe patients who at the
time of surgery were free of nodal involvement has progressed to
nodal disease irrespective ofthe pattern ofE-cadherin expression in
theirprimary tumour. Lossofmembranous E-cadherin expression in
pancreatic carcinoma has been reported to correlate with lymph
node metastasis, high grade and advanced stage (Pignatelli et al,
1994), but for SCCHN it is clearly not any better a prognostic indi-
cator than poor differentiation status for SCCHN. In a previous
study by Schipper et al (1991), E-cadherin expression was corre-
lated with differentiation and seven out of eight nodal metastases
exhibited a complete loss of E-cadherin expression. Contrary to
these findings, in both the present study and an earlier study by
Mattijssen (1993), E-cadherin expression was evident in all lymph
node metastases. In this study, E-cadherin expression was observed
at reduced levels when compared with their corresponding primary
tumours, whereas Mattijssen (1993) found that E-cadherin expres-
sion was in the same range in both lymph nodes and their corres-
ponding primary tumours. The discrepancy in the results may lie in
the fact thatdifferent antibodies were used in the studies. Schipper's
group usedthe monoclonal antibody 6F9 which detects the extracel-
lular domain of the E-cadherin molecule (Frixen et al 1991), while
HECD-1 was used in this study. HECD-1 detects the intracellular
cytoplasmic domain (Takechi et al, 1991). Investigation ofthe other
molecules oftheE-cadherin complex did notprovide any significant
prognostic advantage overE-cadherin alone. Thus, while changes in
the expression of the components of the E-cadherin complex in
SCCHN may be important in creating the conditions in which
metastasis may occur, these changes do not offer a useful adjunct to
current prognostic indicators. These data also serve to emphasize
that the significance ofchanges in the E-cadherin complex may vary
from tumour to tumour and that this heterogeneity is greater than
thatobserved in colon cancer (Kinsella et al, 1993, 1996, manuscript
in preparation).
In conclusion, the components of the E-cadherin cell adhesion
complex are abnormally expressed in all SCCHN. These changes
may be permissive for metastasis but do not appear to determine
the likelihood of metastasis and are no better indicators of patient
outcome than established markers.
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